Showing results 1 to 20 of 22
next >
| Issue Date | Title | Author(s) |
| 22-Mar-2022 | A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer | Fletcher, C; Deng, L; Orafidiya, F; Yuan, W; Lorentzen, M, et al |
| 23-Oct-2016 | A novel role for GSK3β as a modulator of Drosha microprocessor activity and MicroRNA biogenesis | Bevan, CL; Fletcher, CE; Godfrey, JD; Shibakawa, A; Bushell, M, et al |
| 27-Jun-2016 | Advances in genetics: widening our understanding of prostate cancer | Pine, AC; Fioretti, FF; Brooke, GN; Bevan, CL; , et al |
| 16-Aug-2016 | Amplification-free detection of circulating microRNA biomarkers from body fluids based on fluorogenic oligonucleotide-templated reaction between engineered peptide nucleic acid probes: application to prostate cancer diagnosis | Metcalf, GAD; Shibakawa, A; Patel, H; Sita-Lumsden, A; Zivi, A, et al |
| 11-Jul-2019 | Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer | Fletcher, C; Sulpice, E; Combe, S; Shibakawa, A; Leach, D, et al |
| 1-May-2015 | Antiandrogens act as selective androgen receptor modulators at the proteome Level in prostate cancer cells | Brooke, GN; Gamble, SC; Hough, MA; Begum, S; Dart, DA, et al |
| 1-Mar-2022 | Available evidence on HIFU for focal treatment of prostate cancer: a systematic review | Bakavicius, A; Marra, G; Macek, P; Robertson, C; Abreu, AL, et al |
| 30-Apr-2013 | Circulating microRNAs as potential new biomarkers for prostate cancer | Sita-Lumsden, A; Dart, DA; Waxman, J; Bevan, CL; , et al |
| 1-Jul-2020 | Coordinated AR and microRNA regulation in prostate cancer | Eringyte, I; Zamarbide Losada, JN; Powell, SM; Bevan, CL; Fletcher, CE, et al |
| Sep-2017 | Development of a transcriptional repressor based approach for the treatment of prostate cancer | Bevan, Charlotte; Ali, Simak; Fioretti, Flavia Marialucia; |
| 26-Oct-2015 | Dickkopf-3 regulates prostate epithelial cell acinar morphogenesis and prostate cancer cell invasion by limiting TGF-β-dependent activation of matrix metalloproteases. | Romero, D; Al-Shareef, Z; Gorrono-Etxebarria, I; Atkins, S; Turrell, F, et al |
| 11-Feb-2020 | Evaluation of functional outcomes following a second focal-HIFU in men with primary localised, non-metastatic prostate cancer; Results from the High Intensity Focused Ultrasound Evaluation and Assessment of Treatment (HEAT) Registry. | Lovegrove, CE; Peters, M; Guillaumier, S; Arya, M; Afzal, N, et al |
| 23-Nov-2020 | Identification of transcription factor co-regulators that drive prostate cancer progression | Siddappa, M; Wani, SA; Long, MD; Leach, DA; Mathe, EA, et al |
| 25-Jul-2014 | Interplay between steroid signalling and microRNAs: implications for hormone-dependent cancers | Fletcher, CE; Dart, DA; Bevan, CL; , et al |
| 19-Sep-2016 | New roles for nuclear receptors in prostate cancer | Leach, DA; Powell, SM; Bevan, C; |
| 1-Sep-2018 | Novel trifluoromethylated enobosarm analogues with potent anti-androgenic activity in vitro and tissue selectivity in vivo | Dart, DA; Kandil, S; Tommasini-Ghelfi, S; Serrano de Almeida, G; Bevan, CL, et al |
| 1-Apr-2020 | Prostate specific antigen criteria to diagnose failure of cancer control following focal therapy of nonmetastatic prostate cancer using high Intensity focused ultrasound | Huber, PM; Afzal, N; Arya, M; Boxler, S; Dudderidge, T, et al |
| 1-Oct-2012 | Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens | Dart, DA; Brooke, GN; Sita-Lumsden, A; Waxman, J; Bevan, CL, et al |
| 1-May-2018 | Role of androgen receptor variants in prostate cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting | Luo, J; Attard, G; Balk, SP; Bevan, C; Burnstein, K, et al |
| Nov-2020 | Systematic analysis of prognostic miRNAs and isomiRs in prostate cancer | Keun, Hector; Bevan, Charlotte; Rana, Sharmila; |